Pearl Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2006-01-01
- Employees
- 51
- Market Cap
- -
Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT00880490
- Locations
- 🇦🇺
Woolcock Institute of Medical Research, Glebe, New South Wales, Australia
🇦🇺Australian Clinical Research Organisation, Auchenflower, Queensland, Australia
🇳🇿P3 Research, Wellington, New Zealand
Study to Evaluate the Safety and Efficacy of Inhaled PT001 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Pearl Therapeutics, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT00871182
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
🇺🇸Elite Research Institute, Miami, Florida, United States
🇺🇸Spartanburg Medical Research, Spartanburg, South Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath